Physician profile
Michael Zelig
NPI 1578561197
$10,391.14
in general payments reported to CMS, 2019-2025
32 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $490 · 2021: $926 · 2022: $1,553 · 2023: $1,929 · 2024: $1,900 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,133.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,136.12 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,639.75 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $827.22 | 2019-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $669.15 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.14 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $353.61 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $345.36 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $334.62 | 2019-2024 | Dificid |
| Pfizer INC. | $297.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $295.01 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $284.16 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $235.21 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $225.25 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $175.53 | 2021-2023 | |
| Celgene Corporation | $172.48 | 2021-2024 | Zeposia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $167.86 | 2019-2025 | Ocaliva |
| Allergan, INC. | $134.54 | 2019 | |
| Braintree Laboratories, INC. | $91.48 | 2024-2025 | Suflave, Sutab |
| Ardelyx, INC. | $88.70 | 2023-2025 | Ibsrela |
| Shionogi INC | $81.53 | 2019 | |
| Qol Medical, LLC | $76.10 | 2022 | |
| Ferring Pharmaceuticals INC. | $49.75 | 2019-2023 | Cimzia |
| Amgen INC. | $47.29 | 2023-2025 | Amjevita, Uplizna |
| Madrigal Pharmaceuticals | $45.24 | 2024 | Resmetirom |
| Blueprint Medicines Corporation | $44.67 | 2024-2025 | Ayvakit |
| Shire North American Group INC | $42.77 | 2019 | |
| Redhill Biopharma INC. | $30.91 | 2021-2022 | |
| Novo Nordisk INC | $22.78 | 2025 | Wegovy |
| Vivus LLC | $15.35 | 2021 | |
| Echosens North America, INC. | $14.84 | 2023 | Fibroscan |
| Medtronic, INC. | $14.45 | 2021 | |
| Evoke Pharma, INC. | $13.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zelig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.